{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:02:40Z","timestamp":1789394560190,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01551-6","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T16:13:02Z","timestamp":1782576782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4166-5717","authenticated-orcid":false,"given":"Caitlin R.","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1945-2571","authenticated-orcid":false,"given":"Hannah","family":"Goulart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-538X","authenticated-orcid":false,"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-7937","authenticated-orcid":false,"given":"Yesid","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6177-7572","authenticated-orcid":false,"given":"Jan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-4895","authenticated-orcid":false,"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1875-2986","authenticated-orcid":false,"given":"Jeffrey","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9911","authenticated-orcid":false,"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejiroghene","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Garris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"1551_CR1","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/ajh.27708","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Jabbour E. Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2025;100:1205\u201331.","journal-title":"Am J Hematol"},{"key":"1551_CR2","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","journal-title":"Blood"},{"key":"1551_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2018-99-111516","volume":"132","author":"N Goekbuget","year":"2018","unstructured":"Goekbuget N, Dombret H, Zugmaier G, Bonifacio M, Graux C, Faul C, et al. Blinatumomab for minimal residual disease (MRD) in adults with b-cell precursor acute lymphoblastic leukemia (BCP-ALL): median overall survival (OS) is not reached in complete MRD responders at a median follow-up of 53.1 months. Blood. 2018;132:554.","journal-title":"Blood"},{"key":"1551_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/ajh.26634","volume":"97","author":"EJ Jabbour","year":"2022","unstructured":"Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, et al. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10(-4) and higher. Am J Hematol. 2022;97:1135\u201341.","journal-title":"Am J Hematol"},{"key":"1551_CR5","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1182\/blood-2025-1575","volume":"146","author":"C Rausch","year":"2025","unstructured":"Rausch C, Kantarjian H, Jain N, Jorgensen J, Wang S, Wang X, et al. Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher. Blood. 2025;146:1575.","journal-title":"Blood"},{"key":"1551_CR6","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","volume":"406","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Pui CH, Jabbour E. Acute lymphocytic leukaemia. Lancet. 2025;406:950\u201362.","journal-title":"Lancet"},{"key":"1551_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01373-y","volume":"15","author":"NJ Short","year":"2025","unstructured":"Short NJ, Jabbour E, Macaron W, Jain N, Haddad FG, Loghavi S, et al. Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. Blood Cancer J. 2025;15:169.","journal-title":"Blood Cancer J"},{"key":"1551_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353.","journal-title":"N Engl J Med"},{"key":"1551_CR9","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10:e433\u201344.","journal-title":"Lancet Haematol"},{"key":"1551_CR10","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/cncr.33469","volume":"127","author":"E Jabbour","year":"2021","unstructured":"Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, et al. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed\/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021;127:2025\u201338.","journal-title":"Cancer"},{"key":"1551_CR11","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1182\/blood-2025-5131","volume":"146","author":"H Goulart","year":"2025","unstructured":"Goulart H, Kantarjian H, Jain N, Senapati J, Kadia T, DiNardo C, et al. Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia. Blood. 2025;146:5131.","journal-title":"Blood"},{"key":"1551_CR12","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1200\/JCO.24.00490","volume":"42","author":"P Chevallier","year":"2024","unstructured":"Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, et al. Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) Philadelphia chromosome-negative B-Cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2024;42:4327\u201341.","journal-title":"J Clin Oncol"},{"key":"1551_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.23.00546","volume":"42","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N, Wasch R, Kondakci M, Scholl S, et al. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL. J Clin Oncol. 2024;42:273\u201382.","journal-title":"J Clin Oncol"},{"key":"1551_CR14","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1200\/JCO-25-00307","volume":"43","author":"MJ Wieduwilt","year":"2025","unstructured":"Wieduwilt MJ, Yin J, Kour O, Teske R, Stock W, Escherich C, et al. Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed B-cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025;43:3526\u201335.","journal-title":"J Clin Oncol"},{"key":"1551_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1182\/blood-2025-444","volume":"146","author":"M Wieduwilt","year":"2025","unstructured":"Wieduwilt M, Yin J, Kour O, Teske R, Stock W, Escherich C, et al. Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival. Blood. 2025;146:444.","journal-title":"Blood"},{"key":"1551_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood.2023022330","volume":"143","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, et al. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024;143:417\u201321.","journal-title":"Blood"},{"key":"1551_CR17","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1182\/blood-2024-200713","volume":"144","author":"R Gu","year":"2024","unstructured":"Gu R, Gong X, Lin D, Liu K, Zhou C, Wei S, et al. Inotuzumab ozogamicin administration in first remission results in profound and safe minimal residual disease eradication in adult patients with Ph-negative acute lymphoblastic leukemia: findings from a phase 2, single-arm trial. Blood. 2024;144:4199.","journal-title":"Blood"},{"key":"1551_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391:320\u201333.","journal-title":"N Engl J Med"},{"key":"1551_CR19","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood-2025-1566","volume":"146","author":"H Goulart","year":"2025","unstructured":"Goulart H, Kantarjian H, Sasaki K, Jain N, Rausch C, Kadia T, et al. Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis. Blood. 2025;146:1566.","journal-title":"Blood"},{"key":"1551_CR20","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613\u201323.","journal-title":"N Engl J Med"},{"key":"1551_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2024;42:881\u20135.","journal-title":"J Clin Oncol"},{"key":"1551_CR22","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e24\u201334.","journal-title":"Lancet Haematol"},{"key":"1551_CR23","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol. 2024;42:4246\u201351.","journal-title":"J Clin Oncol"},{"key":"1551_CR24","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1182\/blood-2022-157937","volume":"140","author":"G Marconi","year":"2022","unstructured":"Marconi G, Piciocchi A, Chiaretti S, Papayannidis C, Lunghi M, Salutari P, et al. Gimema ALL2418: interim analysis of a Phase IIA study of feasibility and effectiveness of inotuzumab ozogamicin in adult patients with B-cell acute lymphoblastic leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation. Blood. 2022;140:6119\u201321.","journal-title":"Blood"},{"key":"1551_CR25","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391:2219\u201330.","journal-title":"N Engl J Med"},{"key":"1551_CR26","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1182\/blood-2025-2715","volume":"146","author":"Y Valtis","year":"2025","unstructured":"Valtis Y, Sandhu K, Faramand R, Zhang A, Miller K, Hill L, et al. Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: a ROCCA analysis. Blood. 2025;146:2715.","journal-title":"Blood"},{"key":"1551_CR27","doi-asserted-by":"crossref","unstructured":"Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, et al. Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-cell ALL. J Clin Oncol. 2025;43:558\u201366.","DOI":"10.1200\/JCO.24.00321"},{"key":"1551_CR28","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/ajh.26949","volume":"98","author":"NJ Short","year":"2023","unstructured":"Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, et al. Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023;98:1196\u2013203.","journal-title":"Am J Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01551-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01551-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01551-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:02:58Z","timestamp":1789390978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01551-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01551-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EJ: has been a consultant for AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Novartis, Pfizer Canada Inc, and Takeda Onc; CR: none; HG: none; NJ: Research Funding: Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Kite\/Gilead, Mingsight, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave, Novartis, Carna Biosciences, Sana Biotechnology, Kisoji Biotechnology; Advisory Board\/Honoraria: Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies, Kite\/Gilead, Precision Biosciences, Beigene, Cellectis, MEI Pharma, Ipsen, CareDX, MingSight, Autolus, Novalgen; FR: reports grants\/contracts or research funding from AbbVie, Amgen, Astex, Bristol Myers Squibb Company, Macrogenics, Orsenix, Prelude, Taiho Pharmaceutical, and Xencor; personal\/consulting fees from AbbVie, Agios Pharmaceuticals Inc., Amgen, Astellas Pharma, AstraZeneca, Bristol Myers Squibb Company, the Novartis Foundation, and Orsenix; and support for other professional activities from Celgene Corporation outside the submitted work; AM: research funding from Celgene; YA: Research Funding: Jazz Pharmaceuticals, FibroGen, Sun Pharma, BerGenBio, Daiichi Sankyo\/Lilly, Astex Pharmaceuticals; JB: none; MY: Research Funding: Daiichi Sankyo, Pfizer; IK: none; PK: Consulting with Pfizer; JJ: none; SW: none; XW: none; EM: none; RG: none; NS: has been a consultant for Takeda Oncology, AstraZeneca, Amgen, Novartis, and Pfizer and received research funding from Takeda Oncology, Astellas, and Stemline Therapeutics as well as honoraria from Amgen; HK: has received research funding from AbbVie, Amgen, Ascentage Pharma, BMS, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, and Novartis as well as honoraria from AbbVie, Amgen, Amphista Therapeutics, Ascentage Pharma, Astellas Pharma, Biologix, Curis, Ipsen, KAHR, Novartis, Pfizer, Precision Biosciences, Shenzhen TargetRx, and Takeda Oncology.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"154"}}